We hold ourselves to high standards of natural purity, Potency, and Third Party Tested
Tirzepatide, currently recognized as the most effective dual-agonist therapy, targets GLP-1 and GIP receptors but lacks the glucagon component that enhances retatrutide's metabolic impact
Typical Daily Calorie Intake Changes: What Research Shows Observational data from GLP-1 users reveals consistent patterns in energy intake
THE DRIPBaR has nearly 200 additional locations in various stages of development across 16 states
Patients will have regular check-ins at The Re Clinic to monitor progress, manage any side effects, and adjust treatment as needed
Rushing dose increases before your body reaches equilibrium can trigger nausea, vomiting, and gastrointestinal discomfort that may lead to stopping treatment entirely